Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Borgo AB in its a credit institution license application
Mandate

Vinge has advised Borgo AB in its a credit institution license application

March 17, 2021 Corporate Commercial Banking and Finance Insurance Law

Vinge has successfully advised Borgo AB in its license applications as a credit institution. The authorisation was granted by the Swedish FSA on 11 March 2021.

Borgo is an independent mortgage lending company aiming to offer market leading mortgages to Swedish consumers. Borgo’s mortgage products will be offered by ICA Banken, Ikano Bank, Söderberg & Partners and Ålandsbanken, under their brands but with Borgo as lender.

Vinge’s team consisted of, among others Johan Larsson (Corporate), Emma Stuart-Beck, Caroline Krassén and Mikaela Lang (Financial Services), Martin Boström (Commercial Agreements), Paulina Malmberg (Corporate Insurance) and Jolinn Uhlin (Banking & Finance).

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026